mitozolomide

01/01/1990 - "In the treatment of nine human tumor xenografts growing subcutaneously in nude mice, mitozolomide effected a complete or partial remission in 6 out of 9 tumors. "
04/01/1985 - "The efficacy of mitozolomide was as good or better than that of the drugs clinically used against the tumor types tested. "
01/01/1990 - "In a phase I study mitozolomide was given on a once daily for 5 days schedule to 18 patients with a variety of malignancies. "
01/01/1992 - "In conjunction with autologous bone marrow rescue, high-dose mitozolomide was given i.v. to 16 patients with refractory malignancies at doses ranging from 100 to 400 mg/m2 over 1 h. "
01/01/1990 - "In an attempt to relate dose and pharmacokinetic parameters to toxicity, we measured plasma concentrations of mitozolomide in 14 patients with a range of malignancies. "

04/01/1987 - "A phase II trial with mitozolomide was carried out in patients with malignant melanoma, since in preclinical studies this new imidazotetrazine had shown promising effects against human melanoma xenografts. "
04/01/1987 - "It is concluded that orally administered mitozolomide is active against malignant melanoma and seems to have a response rate comparable to those of the most active established drugs."
04/01/1987 - "Twenty-one evaluable patients with advanced malignant melanoma were treated with 115 mg m-2 of mitozolomide, given orally every 6 weeks. "
05/01/1989 - "Phase II studies of mitozolomide in melanoma, lung and ovarian cancer."
05/01/1989 - "Seventy-seven patients were treated with oral mitozolomide to assess the activity of this drug in melanoma, lung and ovarian cancer. "

01/01/1989 - "Phase II trial of mitozolomide in patients with advanced ovarian cancer. "
12/01/1986 - "Further studies were aimed at investigating the susceptibility of freshly isolated human ovarian cancer cells to pharmacologically reasonable mitozolomide concentrations. "
01/01/1988 - "Phase II evaluation of mitozolomide in ovarian cancer."
05/01/1989 - "Phase II studies of mitozolomide in melanoma, lung and ovarian cancer."
05/01/1989 - "Seventy-seven patients were treated with oral mitozolomide to assess the activity of this drug in melanoma, lung and ovarian cancer. "

01/01/1990 - "The cytotoxic drug mitozolomide has been found to cause unpredictably severe thrombocytopenia during phase I and II clinical trials. "
07/01/1985 - "Mitozolomide is well-absorbed; therefore, future studies are recommended using a single-dose schedule orally or iv. In the phase I study reported here, a dose of 115 mg/m2 appeared to be safe, but additional studies have shown that when given orally to an older population, most patients experienced thrombocytopenia less than 50,000 cells/mm3. "

12/01/1986 - "Only in one out of 16 primary cultures of human ovarian cancers was mitozolomide able to induce cell cycle perturbation, suggesting that ovarian carcinoma cells may not be sensitive to this drug."
08/01/1985 - "Mitozolomide and its decomposition product MCTIC were found to be more cytotoxic to BE colon carcinoma cells in vitro than to HT-29 cells, another colon carcinoma cell line. "
07/15/1984 - "In vitro CCRG 81010 is not cross-resistant with the bifunctional alkylating agents against the Walker carcinoma. "
01/01/1990 - "A dose of 3 micrograms/ml mitozolomide, given by continuous exposure, was active (colony number of test less than 30% of the control group) in 12/42 (29%) human tumor xenografts as well as in the four murine tumors, P388, L1210, B16 melanoma and colon carcinoma 38, whereas the two human bone marrows showed no significant suppression of the ability to form colonies in culture. "
04/15/1986 - "Mitozolomide was found to be the most active drug tested in 50% of the lung carcinomas and as active as CCNU in melanomas. "